期刊
CHINESE JOURNAL OF CANCER
卷 31, 期 1, 页码 8-18出版社
SUN YAT SEN UNIV MED SCI WHO
DOI: 10.5732/cjc.011.10281
关键词
mTOR; inhibitor; rapamycin; rapalogs; cancer
类别
资金
- NIH [CA115414]
- American Cancer Society [RSG-08-135-01-CNE]
- NATIONAL CANCER INSTITUTE [R01CA115414] Funding Source: NIH RePORTER
The mammalian target of rapamyc in (mTOR), a serine/threonine protein kinase, acts as a. master switch. for cellular anabolic and catabolic processes, regulating the rate of cell growth and proliferation. Dysregulation of the mTOR signaling pathway occurs frequently in a variety of human tumors, and thus, mTOR has emerged as an important target for the design of anticancer agents. mTOR is found in two distinct multiprotein complexes within cells, mTORC1 and mTORC2. These two complexes consist of unique mTOR-interacting proteins and are regulated by different mechanisms. Enormous advances have been made in the development of drugs known as mTOR inhibitors. Rapamycin, the first defined inhibitor of mTOR, showed effectiveness as an anticancer agent in various preclinical models. Rapamycin analogues (rapalogs) with better pharmacologic properties have been developed. However, the clinical success of rapalogs has been limited to a few types of cancer. The discovery that mTORC2 directly phosphorylates Akt, an important survival kinase, adds new insight into the role of mTORC2 in cancer. This novel finding prompted efforts to develop the second generation of mTOR inhibitors that are able to target both mTORC1 and mTORC2. Here, we review the recent advances in the mTOR field and focus specifically on the current development of the second generation of mTOR inhibitors as anticancer agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据